Clinical trials: Leishmaniasis
Mucocutaneous Leishmaniasis
Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
This study is a Phase 4, open-label, single group study in which at least 40 adult patients undergoing miltefosine treatment for mucocutaneous leishmaniasis (CL and ML) will be assessed by 12-lead ECG for prolongation of the…
- Trial name
- NCT02429518
- Testing
- Miltefosine
- Where
- Bolivia
- Volunteers
- 42 people
- Sponsor
- Knight Therapeutics (USA) Inc
Old World Cutaneous Leishmaniasis
Randomised Clinical Trial in Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan
A four (4) -arm randomised control clinical trial to evaluate miltefosine, thermotherapy and the combination miltefosine-thermotherapy are effective, safe and tolerable alternative treatment options to treat cutaneous…
- Trial name
- NCT04268524
- Testing
- drug: miltefosine with thermotherapy
- Where
- 3 sites in Pakistan
- Volunteers
- 645 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Leishmaniasis, Visceral
Visceral Leishmaniasis in Emilia-Romagna (Leishmania-2019)
According to reports in the literature, from 2012 to date, there has been an increase in the number of diagnosed cases of autochthonous visceral Leishmania in the Province of Bologna.
- Trial name
- NCT06793111
- Where
- 5 sites in Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Cutaneous Leishmaniasis, Cutaneous Leishmaniasis, American
Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis
The goal of this clinical trial is to learn if the drug MILTEFOSINE, used topically in a hydrogel, works to treat non-complicated cutaneous leishmaniasis (CL) in adults.
- Conditions
- Cutaneous Leishmaniasis, Cutaneous Leishmaniasis, American, Topical Administration
- Trial name
- G-MTF01 (NCT07149753)
- Testing
- MILTEFOSINE gel
- Where
- Colombia
- Volunteers
- 15 people
- Sponsor
- Universidad Industrial de Santander
Leishmaniasis, Leptospirosis
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments).
- Conditions
- Leishmaniasis, Leptospirosis, Brucellosis, Q Fever
- Trial name
- SEZAM (NCT06859619)
- Testing
- Peripheral venous blood sample
- Where
- France
- Volunteers
- 183 people
- Sponsor
- University Hospital, Montpellier
Visceral Leishmaniasis, Kala Azar
Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar
A cluster-randomized vector control trial in Bihar, India, and neighboring Nepal, will test the efficacy of long-lasting impregnated bednets (LLINs, Permanets) for reducing visceral leishmaniasis incidence.
- Trial name
- KALANET (NCT00318721)
- Testing
- Long Lasting Impregnated Nets (LLIN)
- Where
- 2 sites in India, Nepal
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Leishmaniasis, Cutaneous
Investigation of an Outbreak Situation of Cutaneous Leishmaniasis Among Military Personnel in French Guiana (CEFELEISH)
Clinical, epidemiological, therapeutic and microbiological investigation of an outbreak of cutaneous Leishmaniasis that occurred among military personnel in French Guiana in 2020.
- Trial name
- CEFELEISH (NCT04888130)
- Testing
- Phylogenetic Analysis, Data collection
- Where
- French Guiana
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier de Cayenne
Invasive Fungal Infections, Neutropenic Fever
Human Bioequivalence Study of Liposomal Amphotericin B for Injection
A single-center, randomized, open-label, single-dose, two-period, double-crossover study to evaluate the bioequivalence of liposomal amphotericin B for injection (test product) manufactured by Sichuan Huiyu Pharmaceutical Co.…
- Conditions
- Invasive Fungal Infections, Neutropenic Fever, Visceral Leishmaniasis
- Trial name
- NCT06983665
- Testing
- Test product (Liposomal amphotericin B for injection, Sichuan Huiyu Pharmaceutical Co., Ltd.), Reference product (AmBisome®, Astellas Pharma US Inc.)
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Leishmaniasis
Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults
The goal of this interventional study is to assess the safety and tolerability of OlPC and to characterize the pharmacokinetics (PK) of OlPC following single, ascending doses administered orally in healthy-fed subjects.
- Trial name
- NCT06124144
- Testing
- Oleylphosphocholine
- Where
- Germany
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Skin and Connective Tissue Diseases, Neglected Tropical Diseases
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited.
- Conditions
- Skin and Connective Tissue Diseases, Neglected Tropical Diseases, Leprosy, Buruli Ulcer
- Trial name
- SkincAIr (NCT07506967)
- Testing
- A mobile app with AI functionality for diagnosing skin-related NTDs
- Where
- 5 sites in Democratic Republic of the Congo, Ethiopia and 3 more
- Volunteers
- 2,420 people
- Sponsor
- Kenya Medical Research Institute
Cutaneous Leishmaniasis
Surveillance for Leishmaniasis Skin Lesions in Mali
This study will examine why some people who become infected with the leishmaniasis parasite develop skin lesions and others do not. The parasite that causes leishmaniasis is transmitted by the bite of a sandfly.
- Trial name
- NCT00344084
- Where
- Mali
- Volunteers
- 1,593 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cutaneous Leishminiasis
Comparison of Intralesional Glucantime With and Without Fractional CO₂ Laser in Adults With Cutaneous Leishmaniasis
Cutaneous leishmaniasis is a common parasitic skin disease causing chronic ulcerative lesions and scarring. Intralesional meglumine antimoniate (Glucantime) is a widely used treatment; however, healing may be prolonged and…
- Trial name
- NCT07652021
- Testing
- Meglumine Antimoniate, Fractional CO₂ laser
- Where
- Pakistan
- Volunteers
- 150 people
- Sponsor
- Combined military hospital Peshawar
Visceral Leishmaniosis, HIV-infection/Aids
Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study
Visceral leishmaniosis (VL) is widely reported in Ethiopia, with about 30% of cases being associated with human immunodeficiency virus (HIV).
- Trial name
- NCT01360762
- Testing
- Pentamidine
- Where
- 3 sites in Ethiopia
- Volunteers
- 74 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Leishmaniasis
Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis
Miltefosine (longer course) will be used to try to improve the cure rate of mucosal leishmaniasis
- Trial name
- NCT00373568
- Testing
- miltefosine: 2.5 mg/kg/day for 42 days
- Where
- Bolivia
- Volunteers
- 25 people
- Sponsor
- AB Foundation
Cutaneous Leishmaniasis, American
Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly
A randomized controlled pilot trial with the aim of identifying the dose of liposomal amphotericin B associated with the highest cure rate in Cutaneous Leishmaniasis (CL).
- Trial name
- NCT06449040
- Testing
- Liposomal amphotericin B (AmBisome®)
- Where
- Brazil
- Volunteers
- 28 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Visceral Leishmaniasis
Evaluation to Assess the Usability of rK28 for the Diagnosis of Visceral Leishmaniasis in Kenya
Visceral leishmaniasis (VL) is a fatal disease caused by Leishmania parasites and transmitted by female phlebotomine sandflies. The disease is a serious public health problem in eastern Africa; including Kenya where an estimated…
- Trial name
- rK28-AccDemo (NCT05386875)
- Testing
- rK28
- Where
- 4 sites in Kenya
- Volunteers
- 625 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Cutaneous Leishmaniasis
Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite
This study will evaluate the safety and immunogenicity of the Leish-111f + MPL-SE vaccine in adult subjects who have no evidence of previous exposure to the Leishmania parasite.
- Trial name
- NCT00121862
- Testing
- Leish-111f + MPL-SE vaccine
- Where
- Colombia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Access to Advanced Health Institute (AAHI)
Visceral Leishmaniasis
Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition
The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of Astellas Pharma US, Inc., in patients…
- Trial name
- NCT03636659
- Testing
- Amphotericin B Liposome, AmBisome (Amphotericin B) Liposome
- Where
- 3 sites in Bangladesh, India
- Volunteers
- 140 people
- Sponsor
- Aurobindo Pharma Ltd
Cutaneous Leishmaniasis
Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
Cutaneous leishmaniasis is typically treated with the parenteral product pentavalent antimony. Miltefosine is an oral agent shown to be active for mucosal leishmaniasis due to L braziliensis in Bolivia and cutaneous leishmaniasis…
- Trial name
- NCT00233545
- Testing
- miltefosine, antimony
- Where
- Bolivia
- Volunteers
- 80 people
- Sponsor
- AB Foundation
Visceral Leishmaniasis
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
The purpose of this study is to assess the efficacy and safety of SSG 30 days alone, PM 21 days alone and SSG and PM as a combination course of 17 days in the treatment of patients with VL.
- Trial name
- NCT00255567
- Testing
- Sodium Stibogluconate, Paromomycin sulphate, SSG and Paromomycin sulphate
- Where
- 5 sites in Ethiopia, Kenya and 2 more
- Volunteers
- 1,142 people
- Sponsor
- Drugs for Neglected Diseases